Pharmacology & ToxicologybioRxiv
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 that Exhibits Antiviral Efficacy in SARS-CoV-2 Infected African Green Monkeys
DOI 10.1021/acs.jmedchem.3c00750
Author
J. P. Bilello
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2020-2023 · peak 3/yrCo-Author Collaboration Network
10 top collaborators · 39 mutual co-author linksFocal author (center)Selected co-authorORCID co-authorUnlinked name
Curved chords = mutual co-authorship9 papers
Recent·Most cited
- BiophysicsbioRxiv
Structural basis for substrate selection by the SARS-CoV-2 replicase
B. F. Malone, J. K. Perry, P. D. B. Olinares…·S. A. Darst
This study uses cryo-EM to reveal how the SARS-CoV-2 RTC discriminates between natural NTPs and the antiviral remdesivir triphosphate, providing insights for antiviral design.
DOI 10.1038/s41586-022-05664-3 - MicrobiologybioRxiv
Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants
J. Pitts, J. Li, J. Perry…·J. P. Bilello
This study assesses the antiviral activity of remdesivir and GS-441524 against multiple SARS-CoV-2 variants, finding they remain effective against Delta, Omicron, and other variants.
DOI 10.1128/aac.00222-22 - BiochemistrybioRxiv
Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir
M. Götte, C. J. Gordon, H. W. Lee…·D. P. Porter
This study investigates how remdesivir's antiviral activity varies across RNA viruses by analyzing its incorporation and inhibition mechanisms in different polymerases.
DOI 10.1016/j.jbc.2021.101529 - MicrobiologybioRxivPreprint
Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.
A. Schafer, D. R. Martinez, J. J. Won…·T. P. Sheahan
This paper evaluates the therapeutic efficacy of GS-621763, an oral prodrug of remdesivir, against SARS-CoV-2 in mice, showing reduced viral load and improved lung function.
DOI 10.1101/2021.09.13.460111 - MicrobiologybioRxiv
A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents
T. N. D. Do, K. Donckers, L. Vangeel…·D. Jochmans
This study develops a SARS-CoV-2 replication model using primary human airway epithelial cells to test antiviral agents, finding that remdesivir and interferons inhibit replication while AT-511 does not.
DOI 10.1016/j.antiviral.2021.105122 - MicrobiologyNature CommunicationsPeer-reviewed
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
P.-Y. Shi, X. Xie, A. E. Muruato…·J. P. Bilello
This paper develops a high-throughput assay using a nanoluciferase-modified SARS-CoV-2 virus to rapidly test neutralizing antibodies and antiviral drugs.
DOI 10.1038/s41467-020-19055-7 - MicrobiologybioRxiv
Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility
J. A. Plante, Y. Liu, J. Liu…·P.-Y. Shi
This study shows the D614G mutation in SARS-CoV-2 increases viral replication and upper respiratory tract viral loads but does not reduce vaccine efficacy or antibody neutralization.
- MicrobiologybioRxiv
Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.
A. J. Pruijssers, A. S. George, A. Schäfer…·T. P. Sheahan
This study shows remdesivir effectively inhibits SARS-CoV-2 in human cells and mice, reducing viral load and improving lung function.